Fresenius Kabi Launches Idacio (biosimilar, adalimumab) in the US for the Treatment of Chronic Autoimmune Diseases
Shots:
- The company reported the commercial availability of citrate-free adalimumab biosimilar Idacio (adalimumab) in the US for use in the treatment of chronic autoimmune diseases. Idacio is available in a self-administered prefilled syringe and a self-administered pre-filled pen
- Idacio, the first immunology biosimilar is indicated for reducing signs and symptoms of RA, juvenile idiopathic arthritis, PsA, ankylosing spondylitis, CD, UC in adults, and PsO
- Additionally, Idacio-branded biosimilar is available in 35+ countries while CMS grants Fresenius Kabi permanent, product-specific Q-Code for Idacio (adalimumab-aacf)
Ref: Businesswire | Image: Fresenius Kabi
Related News:- Fresenius Kabi’s Idacio (biosimilar, adalimumab) Receives the US FDA’s Approval for the Treatment of Chronic Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
